Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 16, 2017 4:30pm
159 Views
Post# 25990337

RE:RE:RE:RE:RE:RE:RE:RE:BEAR-Re News Release

RE:RE:RE:RE:RE:RE:RE:RE:BEAR-Re News ReleaseThanks Bear. This helps many of us understand.

I do realize that statistical significance must be achieved and the smaller p value the higher the probability that the observations were not just a random event but, in fact, a real effect of the drug.

I think I had become fixated on absolute risk reduction as per the post hoc subgroup of patients with CVD, DM and low HDL where the RRR was 77% after 210 days and the absolute risk reduction was 16% points (21% control MACE - 5% apabetalone treated MACE) and I can't remember the p value but it was significant (i.e. p<0.05). 

So subsequently reading about other drugs where I would see something like control = 2% and test = 1.5% so RRR = 25% and let's say p<0.01 (based on a large sample size). Then the absoute risk reduction was 0.5%. So the result is highly significant but the absolute impact seems small. And yet can have a dramatic impact to the drug company.

So I understand how the scientific community can interprete success because of a highly significant p value i.e. the drug had a real impact.

I just want to feel comfortable that the investment community will interprete findings dramatically below 30% RRR even if the p=0.001 for example...that is, if the investment community is aware of and has expectations of the 30% RRR used to power the experiment. If 30% is the investment community's reference point and apabetalone hits 5% RRR with p<0.001 it may be a scientific success and an investmment failure.

From what I saw with ASSURE the investment community is binary (succeeded or failed) but the scientific community is sophisticated and understands the extreme complexities of the science.

I think my biggest concern is on the communications side to the investment community;
  1. Who controls the release of information?
  2. What form does this communications take in terms of content?
  3. How are investors being conditioned currently in terms of how they will interprete success or failure. Your Jardiance example gives me reassurance.
And this raises a challenge for Sarah and Mr Paradis (sorry I can't remember his first name) to begin to set the stage for "the end game" communications.

Oh boy, this time I have really rambled...apologies.

Bear I thank you so much for your insights, scientific knowledge and hard work in enlightening me and many of us I am sure.

Things are sure looking good.
GLTA
Toinv




Bullboard Posts